| 3.07 0.29 (10.43%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies. The company is also advancing ME-344, a mitochondrial inhibitor that targets the oxidative phosphorylation complex, through Phase I development for HER2-negative breast cancer. Completing its portfolio is Pracinostat, an orally administered histone deacetylase inhibitor, which is being evaluated in a Phase II clinical trial for myelodysplastic syndrome. MEI Pharma has forged strategic collaborations, including comprehensive license, development, and commercialization agreements with Kyowa Kirin Company and Helsinn Healthcare SA (the latter also encompassing manufacturing). It further holds a clinical collaboration with BeiGene, Ltd. and a licensing agreement with Presage Biosciences, Inc. Founded in 2000 as Marshall Edwards, Inc., the company rebranded to MEI Pharma, Inc. in July 2012 and maintains its corporate headquarters in San Diego, California.
Thu, 18 Jun 2026
MEI Pharma Inc (MEIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 16 Jun 2026
MEI Pharma Inc Stock (US5846882069): biotech micro-cap in focus amid sparse newsflow - AD HOC NEWS
Tue, 26 May 2026
LITS - Lite Strategy Inc Stock Price and Quote - Finviz
Wed, 10 Sep 2025
MEI Pharma leaves biotech woes behind to rebrand as crypto company - Fierce Biotech
Wed, 10 Sep 2025
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’ - Business Wire
Tue, 05 Aug 2025
MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|